India, April 24 -- Sun Pharmaceutical Industries Limited (Sun Pharma) and Israel-based Moebius Medical have jointly announced the publication of two pivotal studies in Osteoarthritis and Cartilage, the official journal of the Osteoarthritis Research Society International (OARSI). These publications highlight the clinical trial results and underlying mechanism of action for MM-II, a novel non-opioid treatment for symptomatic knee osteoarthritis. MM-II is an innovative formulation composed of large, empty multilamellar liposomes, engineered to reduce joint friction and cartilage wear, thereby alleviating pain. The first published article details the results of a Phase 2b randomized, double-blind, placebo-controlled trial (NCT04506463), which ...